Abstract
The regulatory landscape for neurovascular innovation in the United States remains fragmented, delaying the development and approval of novel diagnostics, drugs, and devices critical to addressing the burden of stroke and other neurovascular disorders. Despite the significant public health impact, regulatory progress has been sluggish, with only two drugs approved for acute stroke in the Food and Drug Administration's (FDA) history, highlighting the need for a shift from a reactive to a proactive, productivity-driven regulatory approach. Current challenges include insufficient stakeholder engagement, opaque decision-making, outdated trial methodologies, and rigid regulatory paradigms that fail to incorporate real-world evidence and emerging technologies. The lack of transparency in trial oversight, inconsistent adjudication processes, and ineffective conflict-of-interest management further hinder trust in regulatory decisions. Additionally, existing safety assessment frameworks require modernization, as outdated adverse event thresholds fail to capture long-term risks and nuanced safety concerns in neurovascular interventions. To address these gaps, regulatory pathways must be realigned with the FDA's broader mission by integrating accelerated approval mechanisms, expanding expert input, and fostering continuous engagement with clinicians, researchers, and industry leaders. Enhancing trial methodologies through standardized imaging core lab processes, adaptive trial designs, and comprehensive safety monitoring will improve the reliability and applicability of clinical data. Furthermore, the recalibration of outcome measures-balancing technical imaging end points with meaningful clinical metrics-ensures that new therapies demonstrate not only efficacy but also real-world benefit. The integration of artificial intelligence, real-world data, and telehealth solutions has the potential to revolutionize regulatory oversight, facilitating dynamic trial adaptations and streamlining approval timelines. Moving forward, regulatory decision-making must be grounded in robust, transparent data rather than outdated paradigms, ensuring that approvals are based on verifiable, patient-centered outcomes rather than arbitrary historical precedents. By modernizing its approach, the FDA can enhance innovation while maintaining rigorous safety and efficacy standards, ultimately accelerating the translation of life-saving neurovascular therapies into clinical practice. This reform-driven strategy offers a clear roadmap for addressing long-standing inefficiencies, ensuring that regulatory oversight supports rather than hinders advancements in stroke and neurovascular care.